Swiss drug major Novartis has seen its net income decline by 91% to $1.47 billion in the fourth quarter, compared to $16.31 billion last year, the company reported Wednesday. Earnings per share stood at $0.69, down from $7.29 a year ago. The profit drop reflects the absence of income from Swiss multinational health care company Roche, of $14.6 billion last year. Novartis held about a third of Roche shares before agreeing to sell back in 2021. Excluding the impact of Roche income, net income grew 2% at constant currencies. Core net income was $3.25 billion or $1.52 per share, compared to $3.14 …